ARTICANZ - Beta (ver 0.91)
Annotated Registry of Trials in Cancer, Australia and New Zealand Ed.
- Results - location/QLD/4120-Greenslopes-Greenslopes-Private-Hospital
Home
By cancer type
By drug class
By site
Data
FAQ
About
⚠
ARTICANZ provides informational content about cancer drug trials in Australia/NZ that is updated weekly but may not be completely accurate, and should not replace medical advice from qualified healthcare professionals. The platform is intended to be useful, providing information "as is" without warranties. Non-medical users must always consult healthcare providers for all clinical decisions.
Search results
21
trial(s) found.
NCT06824467
Advanced
Phase 3
Recruiting
A Phase 3, Randomized, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan Maintenance Treatment With or Without Bevacizumab Versus Standard of Care After Second-line Platinum-based Doublet Chemotherapy in Participants With Platinum-sensitive Recurrent Ovarian Cancer (TroFuse-022/ENGOT-ov84/GOG-3103) (
2870-022
)
anti-Trop2 antibody-drug conjugate
anti-VEGF monoclonal antibody
Fallopian tube cancer
Ovarian cancer
Primary peritoneal serous carcinoma
VIC
3002 - East Melbourne - Epworth Freemasons
QLD
4120 - Greenslopes - Greenslopes Private Hospital
NCT06764485
Advanced
Phase 3
Recruiting
A Phase 3, Two-part, Randomized, Open-label, Adaptive Study Comparing BMS-986365 Versus Investigator's Choice of Therapy Comprising Either Docetaxel or Second Androgen Receptor Pathway Inhibitor (ARPI), in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) -
rechARge
dual AR degrader antagonist
taxane
Castrate-resistant prostate cancer
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2076 - Wahroonga - Sydney Adventist Hospital
2109 - North Ryde - Macquarie University Hospital
2444 - Port Macquarie - Mid North Coast Cancer Institute-Port Macquarie Base Hospital
2560 - Campbelltown - GenesisCare Campbelltown
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3004 - Melbourne, Southbank - Alfred Health
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre
QLD
4120 - Greenslopes - Greenslopes Private Hospital
4215 - Southport - Tasman Oncology
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
5037 - Kurralta Park - Icon Cancer Centre Adelaide
5112 - Elizabeth Vale - Lyell McEwin Hospital
WA
6150 - Murdoch - Fiona Stanley Hospital
TAS
7000 - Hobart - ICON Cancer Care Hobart
NCT06726265
Advanced
Phase 3
Recruiting
TACTI-004
, a Double-Blinded, Randomized Phase 3 Trial in Patients With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) Receiving Eftilagimod Alfa (MHC Class II Agonist) in Combination With Pembrolizumab (PD-1 Antagonist) and Chemotherapy.
T-cell immunostimulatory factor
anti-PD-1 monoclonal antibody
Non-small cell lung cancer
NSW
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
2500 - Wollongong - Cancer Care Wollongong
QLD
4120 - Greenslopes - Greenslopes Private Hospital
4215 - Southport - Gold Coast University Hospital
SA
5112 - Elizabeth Vale - Lyell McEwin Hospital
NCT06646276
Advanced
Phase 3
Recruiting
A Randomized, Double Blind, Multicenter Phase 3 Trial of BMS-986489 (BMS-986012+Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide vs Atezolizumab in Combination With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS). (
CA245-0001
)
anti-PD-1 monoclonal antibody
anti-PD-L1 monoclonal antibody
anti-fucosyl-GM1 monoclonal antibody
platinum-based antineoplastic agent
topoisomerase inhibitor
Small-cell lung cancer
NSW
2560 - Campbelltown - GenesisCare Campbelltown
2747 - Kingswood - Nepean Hospital - Nepean Cancer Care Centre
VIC
3350 - Ballarat - Grampians Health Service's Ballarat Base Hospital
QLD
4120 - Greenslopes - Greenslopes Private Hospital
WA
6150 - Murdoch - Fiona Stanley Hospital
NCT06561386
Advanced
Phase 3
Recruiting
A Phase 3, Randomized, Open-label Study of Nivolumab + Relatlimab Fixed-dose Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy as First-line Treatment for Participants With Non-squamous (NSQ), Stage IV or Recurrent Non-small Cell Lung Cancer and With Tumor Cell PD-L1 Expression ≥ 1% (
RELATIVITY1093
)
anti-LAG3 monoclonal antibody
anti-PD-1 monoclonal antibody
Non-small cell lung cancer
NSW
2065 - St Leonards - GenesisCare North Shore Private Hospital
2250 - Gosford - Central Coast Cancer Centre, Gosford Hospital
VIC
3128 - Box Hill - Box Hill Hospital - Eastern Health
QLD
4032 - Chermside - The Prince Charles Hospital
4120 - Greenslopes - Greenslopes Private Hospital
SA
5112 - Elizabeth Vale - Lyell McEwin Hospital
WA
6150 - Murdoch - Fiona Stanley Hospital
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NZ.3112 - Tauranga - Tauranga Hospital, Bay of Plenty Clinical Trials Unit
NZ.6021 - Wellington - Capital & Coast District Health Board - Wellington Hospital
NZ.9016 - Dunedin - Dunedin Hospital
NCT06400485
Advanced
Phase 1
Recruiting
First-in-Human, Phase 1 Study of AMT-676 in Patients With Advanced Solid Tumors (
AMT-676-01
)
anti-CDH17 antibody-drug conjugate
Solid tumour
NSW
2031 - Randwick - Scientia Clinical Research Ltd
2109 - North Ryde - Macquarie University Hospital
VIC
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre
QLD
4120 - Greenslopes - Greenslopes Private Hospital
WA
6009 - Nedlands - Linear Clinical Research
NCT06353386
Advanced
Phase 1 / Phase 2
Recruiting
MK-
5684-01A
Substudy: A Phase 1/2 Umbrella Substudy of MK-5684-U01 Master Protocol to Evaluate the Safety and Efficacy of MK-5684-based Treatment Combinations or MK-5684 Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC)
CYP11A1 inhibitor
Castrate-resistant prostate cancer
NSW
2109 - North Ryde - Macquarie University Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
QLD
4120 - Greenslopes - Greenslopes Private Hospital
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NCT06326411
Advanced
Phase 1
Recruiting
A Phase I, Open Label Single-arm Two-part Study to Investigate Safety, Pharmacokinetics, and Preliminary Efficacy of Pan-RAF/MEK Glue
NST-628
Oral Tablets in Subject With Solid Tumors Harboring Genetic Alterations in the MAPK Pathway and With Other Solid Tumors
pan-RAF/MEK glue
Glioma
Melanoma
NOT Melanoma
Non-small cell lung cancer
Solid tumour
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2031 - Randwick - Scientia Clinical Research Ltd
VIC
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre
QLD
4120 - Greenslopes - Greenslopes Private Hospital
SA
5042 - Bedford Park - Southern Oncology Clinical Research Unit
NCT06211036
Advanced
Phase 3
Recruiting
A Phase 3, Open-label, Multicenter, Randomized Study of Tarlatamab in Combination With Durvalumab vs Durvalumab Alone in Subjects With Extensive-Stage Small-Cell Lung Cancer Following Platinum, Etoposide and Durvalumab (
DeLLphi-305
)
anti-PD-L1 monoclonal antibody
bispecific T-cell engager,DLL3-targeting
topoisomerase inhibitor
Small-cell lung cancer
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2500 - Wollongong - Wollongong Hospital
VIC
3168 - Clayton - Monash Medical Centre
QLD
4120 - Greenslopes - Greenslopes Private Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT06112314
Advanced
Phase 3
Recruiting
A Phase 3 Randomized, Controlled Study of IMC-F106C Plus Nivolumab Versus Nivolumab Regimens in HLA-A*02:01-Positive Participants With Previously Untreated Advanced Melanoma (
PRISM-MEL-301
anti-PD-1 monoclonal antibody
bispecific T-cell engager,PRAME-targeting
Melanoma
NSW
2065 - Wollstonecraft - Melanoma Institute Australia - The Poche Centre
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
4120 - Greenslopes - Greenslopes Private Hospital (COMPLETED)
WA
6009 - Nedlands - Linear Clinical Research
6009 - Nedlands - One Clinical Research
NCT05910827
Advanced
Phase 1 / Phase 2
cohorts full
A Phase 1b Study to Evaluate HMBD-001 in Combination With Docetaxel With or Without Cetuximab in Participants With Advanced Squamous Non-Small Cell Lung Cancers, and HMBD-001 in Combination With Cetuximab in Participants With Advanced Squamous Cell Cancers (
HMBD-001-103
)
anti-EGFR monoclonal antibody
anti-ERBB3 monoclonal antibody,third generation
taxane
Squamous non-small-cell lung cancer
NSW
2065 - St Leonards - GenesisCare North Shore Private Hospital
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
VIC
3199 - Frankston - Peninsula Health Frankston Hospital
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre (WITHDRAWN)
QLD
4120 - Greenslopes - Greenslopes Private Hospital
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre (WITHDRAWN)
SA
5042 - Bedford Park - Southern Oncology Clinical Research Unit
WA
6009 - Nedlands - Linear Clinical Research
NCT05727904
Advanced
Phase 3
Recruiting
A Phase 3, Multicenter, Randomized, Open-label, Parallel Group, Treatment Study to Assess the Efficacy and Safety of the Lifileucel (LN-144, Autologous Tumor Infiltrating Lymphocytes [TIL]) Regimen in Combination With Pembrolizumab Compared With Pembrolizumab Monotherapy in Participants With Untreated, Unresectable or Metastatic Melanoma (
IOV-MEL-301
)
anti-PD-1 monoclonal antibody
autologous tumor-infiltrating lymphocytes therapy
Melanoma
NSW
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
QLD
4120 - Greenslopes - Greenslopes Private Hospital
WA
6150 - Murdoch - Fiona Stanley Hospital
NCT05549297
Advanced
Phase 3
Recruiting
Phase 2/3 Randomized Study of Tebentafusp as Monotherapy and in Combination With Pembrolizumab Versus Investigator's Choice in HLA-A*02:01-positive Participants With Previously Treated Advanced Melanoma (TEBE-AM) (
IMCgp100-203
)
anti-PD-1 monoclonal antibody
bispecfic T-cell engager,gp100-targeting
Melanoma
NSW
2065 - Wollstonecraft - Melanoma Institute Australia - The Poche Centre
VIC
3004 - Melbourne, Southbank - Alfred Health
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
4120 - Greenslopes - Greenslopes Private Hospital
NCT05270707
Radonc
Recruiting
HyperArc Registry Study (
VAR-2019-01
)
Radiotherapy
cancer therapy
Central nervous system cancer
ACT
2617 - Bruce - Icon Cancer Centre Canberra
QLD
4120 - Greenslopes - Greenslopes Private Hospital
4215 - Southport - ICON Cancer Care
4558 - Maroochydore - Icon Cancer Centre Maroochydore
NCT05086692
Advanced
Phase 1 / Phase 2
Recruiting
A Phase 1/2 Open Label, Dose Escalation and Expansion Study of MDNA11, IL-2 Superkine, Administered Alone or in Combination With Immune Checkpoint Inhibitor in Patients With Advanced Solid Tumors (
ABILITY-1
)
IL-2 superkine
Acral lentiginous melanoma
Bladder cancer
Cancer
Cervical cancer
Clear cell renal cell carcinoma
Colorectal cancer
Cutaneous basal cell carcinoma
Cutaneous melanoma
Cutaneous squamous cell carcinoma
Endometrial cancer
Endometrial carcinoma
Epithelial Ovarian Cancer
Fallopian tube cancer
Gastric cancer
Gastroesophageal junction adenocarcinoma
Head and neck squamous cell carcinoma
Melanoma
Merkel cell carcinoma
Mucosal melanoma
Non-melanoma skin cancer
Non-squamous non-small-cell lung cancer
Oesophageal cancer
Ovarian cancer
Pancreatic adenocarcinoma
Pleural mesothelioma
Primary peritoneal serous carcinoma
Skin cancer
Solid tumour
Squamous non-small-cell lung cancer
Triple-negative breast cancer
dMMR solid cancer
NSW
2031 - Randwick - Scientia Clinical Research Ltd
2109 - North Ryde - Macquarie University Hospital
QLD
4120 - Greenslopes - Greenslopes Private Hospital
4556 - Buderim - Sunshine Coast Haematology and Oncology Clinic
NCT05081609
Advanced
Phase 1 / Phase 2
Recruiting
IL Believe: A Phase 1/2, Open-label, Dose Escalation and Dose Expansion Study to Investigate the Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab, TransCon TLR7/8 Agonist, or Other Anticancer Therapies, in Adult Participants With Locally Advanced or Metastatic Solid Tumor Malignancies (
IL-Believe
)
TLR7/TLR8 agonist
anti-PD-1 monoclonal antibody
Breast cancer
Cervical cancer
Melanoma
Non-small cell lung cancer
Platinum resistant ovarian cancer
Small-cell lung cancer
Solid tumour
NSW
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
VIC
3199 - Frankston - Peninsula Health Frankston Hospital
QLD
4120 - Greenslopes - Greenslopes Private Hospital
4215 - Southport - Tasman Oncology
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
5042 - Bedford Park - Flinders Medical Centre
5065 - Toorak Gardens - Burnside War Memorial Hospital (TERMINATED)
NCT05020236
Haem
Phase 3
Recruiting
AN OPEN-LABEL, 3-ARM, MULTICENTER, RANDOMIZED PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ELRANATAMAB (PF-06863135) MONOTHERAPY AND ELRANATAMAB + DARATUMUMAB VERSUS DARATUMUMAB + POMALIDOMIDE + DEXAMETHASONE IN PARTICIPANTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST 1 PRIOR LINE OF THERAPY INCLUDING LENALIDOMIDE AND A PROTEASOME INHIBITOR (
MAGNETISMM-5
)
anti-CD38 monoclonal antibody
bispecific T-cell engager,BCMA-targeting
glucocorticoid
immunomodulatory imide drug
Multiple myeloma
VIC
3002 - East Melbourne - Epworth Freemasons
3004 - Melbourne, Southbank - Alfred Health
3066 - Epping - Northern Hospital
3121 - Richmond - Epworth Freemasons Hospital
3220 - Geelong - Andrew Love Cancer Centre, University Hospital Geelong
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
4102 - Woolloongabba - Princess Alexandra Hospital
4120 - Greenslopes - Greenslopes Private Hospital
4217 - Benowa - Pindara Private Hospital
WA
6009 - Nedlands - Linear Clinical Research
NZ
NZ.0622 - Takapuna - North Shore Hospital
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NZ.3210 - Hamilton - Waikato Hospital
NZ.4442 - Roslyn - Palmerston North Hospital Cancer Centre - Palmerston North Hospital
NZ.6021 - Wellington - Capital & Coast District Health Board - Wellington Hospital
NCT03486873
Advanced
Phase 3
Recruiting
A Multicenter, Open-label, Phase 3 Study to Evaluate the Long-term Safety and Efficacy in Participants Who Are Currently on Treatment or in Follow-up in Studies That Include Pembrolizumab (
3475-587
)
anti-PD-1 monoclonal antibody
Haematological malignancy
Solid tumour
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2050 - Camperdown - Royal Prince Alfred Hospital - A.W. Morrow Gastroenterology and Liver Centre
2060 - North Sydney - Mater Hospital
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2065 - Wollstonecraft - Melanoma Institute Australia - The Poche Centre
2109 - North Ryde - Macquarie University Hospital
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2170 - Liverpool - Liverpool Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
2444 - Port Macquarie - Mid North Coast Cancer Institute-Port Macquarie Base Hospital
2800 - Orange - Orange Hospital-Cancer Centre Clinical Trials Unit
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3021 - St Albans - Western Health - Sunshine Hospital
3065 - Fitzroy - St Vincent's Hospital Melbourne
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3168 - Clayton - Monash Medical Centre
3355 - Wendouree - Ballarat Oncology & Haematology Clinical Trials Unit
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
4102 - Woolloongabba - Princess Alexandra Hospital
4120 - Greenslopes - Greenslopes Private Hospital
4215 - Southport - Tasman Oncology
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
5011 - Woodville South - The Queen Elizabeth Hospital
WA
6008 - Subiaco - Bendat Family Comprehensive Cancer Centre - St John of God Subiaco Hospital
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NZ.3210 - Hamilton - Waikato Hospital
NZ.6021 - Wellington - Capital & Coast District Health Board - Wellington Hospital
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre
ACTRN12624001484538
Advanced
Phase 2
Not yet recruiting
Phase 2 Trial examining IMMUNE-12 for patients with Glioblastoma Multiforme (GBM). (
GBMI12
)
Ifosfamide
Radiotherapy
Temozolomide
alkylating agent
cancer therapy
cytotoxic chemotherapy
Glioblastoma
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
QLD
4120 - Greenslopes - Greenslopes Private Hospital
ACTRN12624001299594
Radonc
Not Applicable
Not yet recruiting
Evaluation of Feasibility of Response Adapted or Response and anatomical Adapted Stereotactic ablative body radiotherapy (SABR) in advanced mElanoma receiving immunotherapy (
ERASE
)
radiotherapy
Melanoma
QLD
4120 - Greenslopes - Greenslopes Private Hospital
ACTRN12624001298505
Radonc
Not Applicable
Not yet recruiting
Evaluation of Efficacy of Response Adapted and Anatomical Adapted Stereotactic ablative body radiotherapy (SABR) in advanced mElanoma receiving immunotherapy (
ERASE
)
radiotherapy
Melanoma
QLD
4120 - Greenslopes - Greenslopes Private Hospital
Additional search terms:
API and Webpage URLs:
Copy /Bookmark
Filters
Recruitment Status
Recruiting (17)
Not yet recruiting (3)
cohorts full (1)
Recruitment Country and State
QLD (21)
NSW (16)
VIC (15)
WA (10)
SA (8)
NZ (4)
TAS (1)
ACT (1)
Phase
Phase 1 (2)
Phase 1 / Phase 2 (4)
Phase 2 (1)
Phase 3 (11)
Trial Type
Advanced (17)
Radonc (3)
Haem (1)
Cancer Therapy Class
PD-1/PD-L1
48%
PD-1
43%
LAG3
14%
VEGF
10%
androgen axis
10%
PD-L1
10%
PARP
10%
Trop2
5%
AR
5%
CYP17A1
5%
fucosyl-GM1
5%
CDH17
5%
CYP11A1
5%
BRAF
5%
CRAF
5%
MEK
5%
RAF
5%
pan-RAF
5%
DLL3
5%
PRAME
5%
EGFR
5%
ERBB3
5%
gp100
5%
IL-2
5%
ERBB2
5%
TLR7/TLR8
5%
BCMA
5%
CD38
5%
cereblon
5%
Facility
4120 - Greenslopes - Greenslopes Private Hospital (21)
2109 - North Ryde - Macquarie University Hospital (5)
3000 - Melbourne - Peter MacCallum Cancer Centre (5)
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre (4)
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre (4)
6150 - Murdoch - Fiona Stanley Hospital (4)
2298 - Waratah - Calvary Mater Newcastle Medical Oncology (4)
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research (4)
6009 - Nedlands - Linear Clinical Research (4)
4102 - Woolloongabba - Princess Alexandra Hospital (4)
3004 - Melbourne, Southbank - Alfred Health (3)
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre (3)
4215 - Southport - Tasman Oncology (3)
5112 - Elizabeth Vale - Lyell McEwin Hospital (3)
NZ.6021 - Wellington - Capital & Coast District Health Board - Wellington Hospital (3)
2031 - Randwick - Scientia Clinical Research Ltd (3)
2050 - Camperdown - Chris O'Brien Lifehouse (3)
2065 - Wollstonecraft - Melanoma Institute Australia - The Poche Centre (3)
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital (3)
3002 - East Melbourne - Epworth Freemasons (2)
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre (2)
2444 - Port Macquarie - Mid North Coast Cancer Institute-Port Macquarie Base Hospital (2)
2560 - Campbelltown - GenesisCare Campbelltown (2)
2065 - St Leonards - GenesisCare North Shore Private Hospital (2)
5042 - Bedford Park - Southern Oncology Clinical Research Unit (2)
3168 - Clayton - Monash Medical Centre (2)
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre (2)
3199 - Frankston - Peninsula Health Frankston Hospital (2)
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre (2)
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre (2)
NZ.3210 - Hamilton - Waikato Hospital (2)
2076 - Wahroonga - Sydney Adventist Hospital (1)
5037 - Kurralta Park - Icon Cancer Centre Adelaide (1)
7000 - Hobart - ICON Cancer Care Hobart (1)
2500 - Wollongong - Cancer Care Wollongong (1)
4215 - Southport - Gold Coast University Hospital (1)
2747 - Kingswood - Nepean Hospital - Nepean Cancer Care Centre (1)
3350 - Ballarat - Grampians Health Service's Ballarat Base Hospital (1)
2250 - Gosford - Central Coast Cancer Centre, Gosford Hospital (1)
3128 - Box Hill - Box Hill Hospital - Eastern Health (1)
4032 - Chermside - The Prince Charles Hospital (1)
NZ.3112 - Tauranga - Tauranga Hospital, Bay of Plenty Clinical Trials Unit (1)
NZ.9016 - Dunedin - Dunedin Hospital (1)
2500 - Wollongong - Wollongong Hospital (1)
6009 - Nedlands - One Clinical Research (1)
2617 - Bruce - Icon Cancer Centre Canberra (1)
4215 - Southport - ICON Cancer Care (1)
4558 - Maroochydore - Icon Cancer Centre Maroochydore (1)
4556 - Buderim - Sunshine Coast Haematology and Oncology Clinic (1)
5042 - Bedford Park - Flinders Medical Centre (1)
5065 - Toorak Gardens - Burnside War Memorial Hospital (1)
3066 - Epping - Northern Hospital (1)
3121 - Richmond - Epworth Freemasons Hospital (1)
3220 - Geelong - Andrew Love Cancer Centre, University Hospital Geelong (1)
4217 - Benowa - Pindara Private Hospital (1)
NZ.0622 - Takapuna - North Shore Hospital (1)
NZ.4442 - Roslyn - Palmerston North Hospital Cancer Centre - Palmerston North Hospital (1)
2050 - Camperdown - Royal Prince Alfred Hospital - A.W. Morrow Gastroenterology and Liver Centre (1)
2060 - North Sydney - Mater Hospital (1)
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital (1)
2170 - Liverpool - Liverpool Hospital (1)
2800 - Orange - Orange Hospital-Cancer Centre Clinical Trials Unit (1)
3021 - St Albans - Western Health - Sunshine Hospital (1)
3065 - Fitzroy - St Vincent's Hospital Melbourne (1)
3355 - Wendouree - Ballarat Oncology & Haematology Clinical Trials Unit (1)
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital (1)
5011 - Woodville South - The Queen Elizabeth Hospital (1)
6008 - Subiaco - Bendat Family Comprehensive Cancer Centre - St John of God Subiaco Hospital (1)
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre (1)
Cancer Type
Cancer
Solid tumour
Lung cancer
Respiratory tract cancer
Thoracic cancer
Melanoma
Non-small cell lung cancer
Gynaecological cancer
High-grade serous carcinoma of the ovary, fallopian tube, and peritoneum
Ovarian cancer
Urogenital cancer
Carcinoma
Neuroendocrine carcinoma
Small-cell lung cancer
Small-cell neuroendocrine carcinoma
Central nervous system cancer
Neurological cancer
Fallopian tube cancer
Peritoneal cancer
Primary peritoneal serous carcinoma
Castrate-resistant prostate cancer
Male genital cancers
Prostate adenocarcinoma
Prostate cancer
Glioma
Squamous non-small-cell lung cancer
Breast cancer
Cervical cancer
Epithelial Ovarian Cancer
HPV-related cancer
HPV16-positive cancer
Viral-related cancer
Haematological malignancy
Acral lentiginous melanoma
Biomarker-defined solid tumour
Bladder cancer
Breast adenocarcinoma
Clear cell renal cell carcinoma
Colorectal cancer
Cutaneous basal cell carcinoma
Cutaneous melanoma
Cutaneous squamous cell carcinoma
Endometrial cancer
Endometrial carcinoma
Exocrine pancreatic cancer
Gastric cancer
Gastric carcinoma
Gastroesophageal cancer
Gastroesophageal junction adenocarcinoma
Gastrointestinal cancer
Head and neck cancer
Head and neck squamous cell carcinoma
Kidney cancer
Lower gastrointestinal cancer
MSI-H/dMMR solid tumour
Merkel cell carcinoma
Mesothelioma
Mucosal melanoma
Non-melanoma skin cancer
Non-squamous non-small-cell lung cancer
Oesophageal cancer
Pancreatic adenocarcinoma
Pancreatic cancer
Pancreatobiliary cancer
Pleural mesothelioma
Skin cancer
Triple-negative breast cancer
Upper gastrointestinal cancer
dMMR solid cancer
High-grade serous ovarian cancer
Ovarian adenocarcinoma
Ovarian serous carcinoma
Platinum resistant ovarian cancer
Multiple myeloma
Plasma cell disorder
Glioblastoma
High-grade glioma
Malignant glioma
URLs for this search
API URL:
Copy
Bookmarkable URL:
Copy